VIDEO: Gene therapy shows promise for treatment of wet AMD

ByAllen C. Ho, MD

ByAnthony DeFino

Fact checked byEamon N. Dreisbach

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses recent breakthroughs demonstrating that gene therapy is a viable option for treating wet age-related macular degeneration.

According to Ho, gene therapies administered intravitreally or in the subretinal space can effectively deliver transgenes and spur the growth of therapeutic proteins.

“We have really strong evidence from multiple programs ... that administering these transgenes in those spaces can produce durable, therapeutic levels of these anti-VEGF therapeutics so that the eye makes its own medicine,” Ho said.

Published by:

Sources/Disclosures

Collapse

Source:

Ho AC. Gene therapy for nAMD 2025. Presented at: Retina 2025; Jan. 18-24, 2025; Koloa, Hawaii.

Disclosures: Ho reports having financial disclosures for multiple companies in the gene therapy space including advisory roles for AbbVie, Adverum, Regenxbio and 4D Molecular Therapeutics.

Hawaiian Eye/Retina Meeting

Read more

VIDEO: Gene therapy shows promise for treatment of wet AMD

Related Content